Agency promises one-to-two month drug reviews for Sanofi’s diabetes drug and Regeneron gene therapy, among others
WASHINGTON — The Food and Drug Administration on Thursday announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program offering an expedited drug review to companies with products that align with the agency’s... [441 chars]